De Novo Pharmaceuticals

About:

De Novo Pharmaceuticals is an emerging computational drug design company.

Top Investors: MVM Life Science Partners, Avlar BioVentures, Merlin Biomed, Quester, The Cambridge Gateway Fund

Description:

De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.